New hope for hard-to-treat myeloma: experimental combo shows promise
Disease control
Recruiting now
This study tests a new drug, F182112, given with other treatments for people whose multiple myeloma has returned or stopped responding to prior therapy. About 90 participants will receive the combination to see if it shrinks tumors and how safe it is. The goal is to control the d…
Phase: PHASE2 • Sponsor: Shandong New Time Pharmaceutical Co., LTD • Aim: Disease control
Last updated May 11, 2026 20:53 UTC